|Sounds like oral Kynapid development will proceed...|
Cardiome Provides Update for Oral Vernakalant Development Program
NASDAQ: CRME TSX: COM
VANCOUVER, Dec. 29 /CNW/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX:
COM) today announced that it has been advised by its partner, Merck
(known as MSD outside the United States and Canada), that the current
review of vernakalant (oral) is complete, and that Merck has informed
Cardiome of its next steps in clinical development for vernakalant
(oral) beginning in 2011.
"We are delighted that Merck has confirmed its plans for development of
vernakalant (oral), and we look forward to working with them as they
advance the vernakalant (oral) program to maximize its full potential,"
said Doug Janzen, Chief Executive Officer and President of Cardiome.
Merck Cardiome Agreement
In April 2009, Cardiome and Merck announced a collaboration and license
agreement for the development and commercialization of vernakalant.
The agreement provides Merck Sharp and Dohme Corp. (formerly known as
Merck & Co., Inc.) with exclusive global rights to vernakalant oral
formulation for the maintenance of normal heart rhythm in patients with
atrial fibrillation (AF), and provides another Merck affiliate, Merck
Sharp & Dohme (Switzerland) GmbH, with exclusive rights outside of the
United States, Canada and Mexico to vernakalant IV formulation for
rapid conversion of recent onset AF to sinus rhythm in adults.